Table 2.
Subgroup analysis of clinical response.
| Items, No. (%) | ORR | Non-ORR | P-value | DCR | Non-DCR | P-value |
|---|---|---|---|---|---|---|
| Age | 0.963 | 0.680 | ||||
| ≤65 years | 37 (57.8) | 27 (42.2) | 55 (85.9) | 9 (14.1) | ||
| >65 years | 8 (57.1) | 6 (42.9) | 13 (92.9) | 1 (7.1) | ||
| Gender | 1.000 | 1.000 | ||||
| Female | 4 (57.1) | 3 (42.9) | 6 (85.7) | 1 (14.3) | ||
| Male | 41 (57.7) | 30 (42.3) | 62 (87.3) | 9 (12.7) | ||
| HBV | 0.224 | 0.107 | ||||
| No | 12 (70.6) | 5 (29.4) | 17 (100.0) | 0 (0.0) | ||
| Yes | 33 (54.1) | 28 (45.9) | 51 (83.6) | 10 (16.4) | ||
| ECOG PS score | 0.673 | 0.348 | ||||
| 0 | 13 (59.1) | 9 (40.9) | 21 (95.5) | 1 (4.5) | ||
| 1 | 31 (56.4) | 24 (43.6) | 46 (83.6) | 9 (16.4) | ||
| 2 | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
| Child–Pugh class | 0.608 | 1.000 | ||||
| A | 35 (59.3) | 24 (40.7) | 51 (86.4) | 8 (13.6) | ||
| B | 10 (52.6) | 9 (47.4) | 17 (89.5) | 2 (10.5) | ||
| Extrahepatic metastasis | 0.522 | 0.172 | ||||
| No | 21 (61.8) | 13 (38.2) | 32 (94.1) | 2 (5.9) | ||
| Yes | 24 (54.5) | 20 (45.5) | 36 (81.8) | 8 (18.2) | ||
| Vascular invasion | 0.630 | 0.086 | ||||
| No | 27 (60.0) | 18 (40.0) | 42 (93.3) | 3 (6.7) | ||
| Yes | 18 (54.5) | 15 (45.5) | 26 (78.8) | 7 (21.2) | ||
| BCLC stage | 0.777 | 0.155 | ||||
| B | 15 (60.0) | 10 (40.0) | 24 (96.0) | 1 (4.0) | ||
| C | 30 (56.6) | 23 (43.4) | 44 (83.0) | 9 (17.0) | ||
| CNLC stage | 0.788 | 0.518 | ||||
| Ib | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
| IIa | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
| IIb | 7 (53.8) | 6 (46.2) | 13 (100.0) | 0 (0.0) | ||
| IIIa | 11 (61.1) | 7 (38.9) | 16 (88.9) | 2 (11.1) | ||
| IIIb | 25 (55.6) | 20 (44.4) | 37 (82.2) | 8 (17.8) | ||
| AFP | 0.070 | 0.290 | ||||
| <400 ng/ml | 31 (66.0) | 16 (34.0) | 43 (91.5) | 4 (8.5) | ||
| ≥400 ng/ml | 13 (44.8) | 16 (55.2) | 24 (82.8) | 5 (17.2) | ||
| UK | 1 (50.0) | 1 (50.0) | 1 (50.0) | 1 (50.0) | ||
| Hepatectomy | 0.384 | 1.000 | ||||
| No | 30 (54.5) | 25 (45.5) | 48 (87.3) | 7 (12.7) | ||
| Yes | 15 (65.2) | 8 (34.8) | 20 (87.0) | 3 (13.0) | ||
| Times of previous TACE | 0.617 | 0.490 | ||||
| 0 | 12 (57.1) | 9 (42.9) | 18 (85.7) | 3 (14.3) | ||
| 1 | 16 (61.5) | 10 (38.5) | 23 (88.5) | 3 (11.5) | ||
| 2 | 9 (64.3) | 5 (35.7) | 13 (92.9) | 1 (7.1) | ||
| 3 | 4 (66.7) | 2 (33.3) | 6 (100.0) | 0 (0.0) | ||
| >3 | 4 (36.4) | 7 (63.6) | 8 (72.7) | 3 (27.3) | ||
| Previous treatment lines | 0.577 | 0.538 | ||||
| First-line | 37 (58.7) | 26 (41.3) | 56 (88.9) | 7 (11.1) | ||
| Second-line | 7 (50.0) | 7 (50.0) | 11 (78.6) | 3 (21.4) | ||
| > Second-line | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | ||
| Times of TACE, No. (%) | 0.356 | 0.199 | ||||
| ≤3 | 36 (55.4) | 29 (44.6) | 55 (84.6) | 10 (15.4) | ||
| >3 | 9 (69.2) | 4 (30.8) | 13 (100.0) | 0 (0.0) | ||
| Timing of camrelizumab administration, No. (%) | 1.000 | 0.574 | ||||
| Before TACE | 4 (66.7) | 2 (33.3) | 5 (83.3) | 1 (16.7) | ||
| After TACE | 41 (56.9) | 31 (43.1) | 63 (87.5) | 9 (12.5) | ||
| Treatment cycle of camrelizumab | 0.176 | 1.000 | ||||
| Q2W | 0 (0.0) | 2 (100.0) | 2 (100.0) | 0 (0.0) | ||
| Q3W | 45 (59.2) | 31 (40.8) | 66 (86.8) | 10 (13.2) | ||
| Cycles of camrelizumab, No. (%) | 0.023 | 0.080 | ||||
| ≤2 | 2 (25.0) | 6 (75.0) | 8 (100.0) | 0 (0.0) | ||
| 3–4 | 11 (45.8) | 13 (54.2) | 18 (75.0) | 6 (25.0) | ||
| >4 | 32 (69.6) | 14 (30.4) | 42 (91.3) | 4 (8.7) | ||
| Interval between TACE and camrelizumab administration | 0.454 | 0.658 | ||||
| Within 7 days | 40 (59.7) | 27 (40.3) | 58 (86.6) | 9 (13.4) | ||
| Within 8 to 14 days | 3 (60.0) | 2 (40.0) | 5 (100.0) | 0 (0.0) | ||
| Within 15 to 28 days | 2 (33.3) | 4 (66.7) | 5 (83.3) | 1 (16.7) | ||
| Treatment regimen | 0.341 | 1.000 | ||||
| Monotherapy of camrelizumab | 21 (52.5) | 19 (47.5) | 35 (87.5) | 5 (12.5) | ||
| Combination therapy with TKI | 24 (63.2) | 14 (36.8) | 33 (86.8) | 5 (13.2) |
ORR, objective response rate; DCR, disease control rate; HBV, hepatitis B virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer; AFP, alpha-fetoprotein; UK, unknown; TACE, transarterial chemoembolization; Q2W, every 2 weeks; Q3W, every 3 weeks; TKI, tyrosine kinase inhibitors. The bold values indicate the comparison with statistical significance.